Loading news...
Workday (WDAY) is experiencing a decline following its 4Q26 report, as investors focus on a cautious FY27 subscription revenue forecast despite surpassing Q4 pr
M&G PLC cut its position in shares of HUTCHMED (China) Limited Sponsored ADR (NASDAQ: HCM) by 21.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 204,432 shares of the company's stock after selling 55,185 shares during the period. M&G
NORWALK, CT , Feb. 11, 2026 (GLOBE NEWSWIRE) -- HCM IV Acquisition Corp (the “Company”), a blank check company whose business purpose is to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, announced today that it has priced its initial public offering of 25,000,000 units at $10.00 per unit. Each unit consists of one Class A ordinary share and one-quarter of one redeemable warrant. The units will be listed on the Nasdaq Global Market (“Nasdaq”) and will begin trading tomorrow, February 12, 2026, under the ticker symbol “HACQU." Each whole warrant is exercisable to purchase one Class A ordinary share of the Company at a price of $11.50 per share. Only whole warrants are exercisable and will trade. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on the Nasdaq under the symbols “HACQ” and “HACQW,” respectively.
These human capital management stocks are starting to make an argument for being in oversold territory following January's strong U.S. Jobs report.
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 06, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2025 on Thursday, March 5, 2026 at 6:00 am Eastern Standard Time (EST) / 11:00 am Greenwich Mean Time (GMT) / 7:00 pm Hong Kong Time (HKT).
HUTCHMED (China) Limited Sponsored ADR (NASDAQ: HCM - Get Free Report) shares saw strong trading volume on Friday. 48,356 shares changed hands during mid-day trading, a decline of 5% from the previous session's volume of 51,076 shares.The stock last traded at $15.49 and had previously closed at $15.85. Analysts Set New Price Targets A number
Vancouver, British Columbia--(Newsfile Corp. - January 15, 2026) - Homeland Uranium Corp. (TSXV: HLU) (OTCQB: HLUCF) (FSE: D3U) ("Homeland" or the "Company"), at the request of the TSX Venture Exchange (the "TSXV"), announces a previous engagement with HoldCo Markets Advisory Inc. ("HCM") pursuant to the terms of an investor relations services agreement entered between the Company and HCM dated January 24, 2025 (the "HCM Agreement") pursuant to which HCM agreed to provide the Company with research and coverage reports on the Company and its peers, and information distribution and social media services (collectively, the "Services") for a one-year term from January 24, 2025 (the "Effective Date") until January 24, 2026 (the "Term"). HCM is a Canadian company focused on specialized investment management for the junior/mid-cap metals and mining sector.
— First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after progression on prior EGFR-TKI treatment —
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--BMS Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos in Adolescents with Symptomatic oHCM.
HUTCHMED (China) Limited Sponsored ADR (NASDAQ: HCM - Get Free Report) has received a consensus recommendation of "Hold" from the five ratings firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and one has issued a buy recommendation
The consensus price target hints at a 55.9% upside potential for HUTCHMED (HCM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
HUTCHMED (China) Limited (NASDAQ: HCM) on Tuesday shared data from the Phase 3 registration part of the ESLIM-02 clinical trial of sovleplenib in adult patients with warm antibody autoimmune hemolytic anemia (wAIHA).
— Delivers rapid, durable responses in wAIHA, the more common form of this potentially life-threatening disease —
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the Phase III part of the Phase II/III trial to evaluate the efficacy of the combination of surufatinib, camrelizumab, nab-paclitaxel and gemcitabine as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma (“PDAC”) in China. The first patient received the first dose on December 30, 2025.
— NDA supported by positive Phase II registration study data in Chinese patients; follows Breakthrough Therapy Designation granted in 2023 —
Edgewise Therapeutics, Inc. maintains a Buy rating, driven by favorable interim 12-week safety data for EDG-7500 in phase 2 CIRRUS-HCM and multiple 2026 catalysts. EDG-7500 demonstrated strong tolerability and no clinically meaningful LVEF reductions, potentially differentiating it from cardiac myosin inhibitors for HCM treatment. Key 2026 catalysts include phase 2 CIRRUS-HCM efficacy data in Q2 2026 and potential phase 3 initiation for EDG-7500 in Q4 2026, targeting both oHCM and nHCM patients.
— NDA supported by results from a Phase II registration trial in China — — Second most common form of liver cancer after hepatocellular carcinoma, with generally poorer long-term survival in comparison — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 29, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for fanregratinib (HMPL-453) for the treatment of adult patients with advanced, metastatic or unresectable intrahepatic cholangiocarcinoma (“ICC”) with fibroblast growth factor receptor (“FGFR”) 2 fusion/rearrangement who have previously received systemic therapy has been accepted and granted priority review by the China National Medical Products Administration (“NMPA”).
BOULDER, Colo., Dec. 24, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), today announced positive updates from the ongoing CIRRUS-HCM, Phase 2 clinical trial of EDG-7500, a novel oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with hypertrophic cardiomyopathy (HCM) without impacting systolic function, two central clinical goals in the current management of HCM.
— First-in-human trial of candidate from the next-generation ATTC platform — — Simultaneous China and global clinical development strategy to expedite development process — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces the initiation of its global Phase I clinical development program for HMPL-A251, a first-in-class PI3K/PIKK-HER2 Antibody-Targeted Therapy Conjugate (“ATTC”) comprising a highly selective and potent PI3K/PIKK inhibitor payload conjugated to a humanized anti-HER2 IgG1 antibody via a cleavable linker.
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 27, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Medical Oncology (“ESMO”) Asia Congress 2025, taking place on December 5-7, 2025 in Singapore, and the American Society of Hematology (“ASH”) Annual Meeting taking place on December 6-9, 2025 in Orlando, USA.